{"id":39544,"date":"2023-10-30T11:54:22","date_gmt":"2023-10-30T10:54:22","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=39544"},"modified":"2023-11-02T16:05:24","modified_gmt":"2023-11-02T15:05:24","slug":"genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/","title":{"rendered":"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44)"},"content":{"rendered":"\n

Nordic | Biotech & Healthcare<\/strong> Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates of clinical trials, acquisitions, insider trading, price targets, right issues, etc. <\/em>We also present the top 3 best performing stocks in the Nordics each week.<\/p>\n\n\n\n

In the past week, <\/strong>Genmab announced positive phase 3 data for TIVDAK in partnership with Seagen, Gubra raised its guidance for 2023, Pila Pharma announced a rights issue of 26 MSEK, and CS Medica registered a CANNASEN in Australia. IO Biotech fell 19% following what the company describes as “encouraging” data from a phase 2 study. The best healthcare stock in the Nordics rose almost 100%.<\/strong><\/p>\n\n\n\n

In the past week, 13 of the 20 listed Danish biotech companies published news. 6 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 185% increase.<\/strong><\/p>\n\n\n\n

\n\n\n\n

IMPACT STOCKS IN THE NORDICS<\/em><\/strong> We have launched a brand new newsletter that dives deep into impact stocks in the Nordics. The newsletter can help you to invest more sustainably in the businesses of tomorrow. We track the development of multiple sectors including energy production, waste management, and carbon capture. We follow over 100 large and small companies such as Vestas, \u00d8rsted and Ekobot. Read the first edition here<\/a>.<\/p>\n\n\n\n

\n
Register for the Nordic | Impact newsletter<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish Company news the past week<\/strong><\/p>\n\n\n\n

Ascendis Pharma<\/strong><\/p>\n\n\n\n

Ascendis Presents Updated and New TransCon\u2122 IL-2 \u03b2\u2044\u03b3 Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Biosergen<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/strong><\/p>\n\n\n\n

Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

CS Medica<\/strong><\/a><\/p>\n\n\n\n

CANNASEN\u00ae is now a registered brand in Australia<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Curasight<\/strong><\/a><\/p>\n\n\n\n

Curasight got a new price target from Redeye of 29DKK in their base-case scenario.<\/p>\n\n\n\n

Evaxion Biotech<\/strong><\/p>\n\n\n\n

New and Exciting Clinical Data on Evaxion\u2019s AI-Immunology\u2122-Based Personalized Cancer Vaccines to be Presented<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Expres2ion<\/strong><\/p>\n\n\n\n

Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB<\/em> (Link<\/a>)<\/p>\n\n\n\n

Background and rationale for the proposed incentive program 2023\/2026 (Link<\/a>)<\/p>\n\n\n\n

Fluoguide<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/strong><\/p>\n\n\n\n

TIVDAK\u00ae (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Gubra<\/strong><\/p>\n\n\n\n

Gubra opens its first US office in Boston<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Gubra raises financial guidance for full-year 2023 (Link<\/a>)<\/p>\n\n\n\n

Gubra enters into a Market Maker Agreement (Link<\/a>)<\/p>\n\n\n\n

Initiator Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/strong><\/p>\n\n\n\n

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Pila Pharma<\/strong><\/p>\n\n\n\n

Pila Pharma’s Board of Directors has resolved to carry out a Rights Issue of Shares of approximately SEK 26.2 Million (Link<\/a>)<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/strong><\/p>\n\n\n\n

Positive data on Saniona\u2019s SAN711 in epilepsy presented at SfN<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

Scandion Oncology<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/strong><\/p>\n\n\n\n

SynAct Pharma publishes Q3 2023 interim report<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em> (Link<\/a>)<\/p>\n\n\n\n

ViroGates<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Y-mAbs Therapeutics<\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

2cureX<\/strong><\/p>\n\n\n\n

NOTICE TO ATTEND THE EXTRAORDINARY GENERAL MEETING OF 2CUREX AB <\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em>(Link<\/a>)<\/p>\n\n\n\n

SELECTED CASES<\/strong><\/p>\n\n\n\n

\n
\n

Curasight<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment Case<\/a><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

CS Medica<\/a><\/strong><\/h2>\n\n\n\n
\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\n
Investment case<\/mark><\/a><\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

SHARE PRICE DEVELOPMENTS – Dansih stocks<\/em><\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks delivered a negative share price performance last week of 1.3%. CS Medica <\/strong>rose 28% after their product, CANNASEN, got registred in Australia. Cessatech <\/strong>also performed well with a 10% increase after the Paediatric Committee agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children. IO Biotech<\/strong> fell 19% following what the company called “encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab”. The stock intially rose following the news, but ended 19% down for the week. The best stocks year-to-date include Curasight, Cessatech, Fluoguide, <\/strong>and Saniona<\/strong> after soaring 74-185%. Overall, the Danish biotech and healthcare stocks are in negative terrotory this year with a year-to-date return of -3.3%<\/strong>.<\/p>\n\n\n\n

Read more about Curasight (in Danish):<\/strong><\/mark> Positive studiedata mod lungekr\u00e6ft styrker Curasights st\u00e6rke kursudvikling<\/a><\/p>\n\n\n\n

Overview of share price developments the past week, year-to-date and last twelve months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

DEVELOPMENTS IN NORDIC BIOTECH & HEALTHCARE<\/strong><\/p>\n\n\n\n

In the past week, Kapital Partner Nordic Healthcare Index (KPHC)<\/strong> fell 3% to 57.12. Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics. It includes large cap companies such as Novo Nordisk and Genmab as well as smaller companies as Curasight. In the past year, it has significantly underperformed relative to the C25-index in Copenhagen and S30-index in Stockholm, while the Kapital Parnter Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’ trajectory.<\/p>\n\n\n\n

The index development for Kapital Partner Healthcare Index the past 12 months<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The 3 best performing Nordic biotech & healthcare stocks the past week<\/strong><\/p>\n\n\n\n

Fluicell AB (91%)<\/strong> (Nordnet<\/a>) conducts research and development in processing the composition of cells in the development of new pharmaceuticals. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze and finally process cells. In addition, there is expertise in 2D \/ 3D printing.<\/p>\n\n\n\n

Tendo AB (85%)<\/strong> (Nordnet<\/a>) is a medical technology company that develops medical technology robotic aids for spinal cord injury. The company’s products mainly include Tendo OneGrip, a glove with a so-called integrated exoskeleton that assists people with limited hand function as a result of a spinal cord injury. In the past week, the company got a patent for OneGrip in Australia.<\/p>\n\n\n\n

Prostatype Genomics AB (69%) <\/strong>(Nordnet<\/a>) specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. In the past week, the company got positive results in a study with Taiwanese patients. Read more here<\/a>.<\/p>\n\n\n\n

Sources: Eikon & Nordnet<\/p>\n","protected":false},"excerpt":{"rendered":"

Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates of clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best performing stocks in the Nordics each week. In the past week, […]<\/p>\n","protected":false},"author":11,"featured_media":39226,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[29,141,163,113],"tags":[],"class_list":["post-39544","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-investeringscases","category-market-cases","category-sector-cases","category-sektorcases"],"acf":[],"yoast_head":"\nGenmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44) | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44) | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates of clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best performing stocks in the Nordics each week. In the past week, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-30T10:54:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-02T15:05:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44)\",\"datePublished\":\"2023-10-30T10:54:22+00:00\",\"dateModified\":\"2023-11-02T15:05:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\"},\"wordCount\":1032,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg\",\"articleSection\":[\"Investeringscases\",\"Market Cases\",\"Sector cases\",\"Sektorcases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\",\"name\":\"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44) | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg\",\"datePublished\":\"2023-10-30T10:54:22+00:00\",\"dateModified\":\"2023-11-02T15:05:24+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Sector cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/sector-cases\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44) | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/","og_locale":"en_US","og_type":"article","og_title":"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44) | Kapital Partner A\/S","og_description":"Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates of clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best performing stocks in the Nordics each week. In the past week, […]","og_url":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2023-10-30T10:54:22+00:00","article_modified_time":"2023-11-02T15:05:24+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44)","datePublished":"2023-10-30T10:54:22+00:00","dateModified":"2023-11-02T15:05:24+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/"},"wordCount":1032,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg","articleSection":["Investeringscases","Market Cases","Sector cases","Sektorcases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/","url":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/","name":"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44) | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg","datePublished":"2023-10-30T10:54:22+00:00","dateModified":"2023-11-02T15:05:24+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2023\/10\/NORDIC-BIOTECH-HEALTHCARE.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/genmab-seagen-announces-positive-phase-3-data-best-stock-up-by-100-cessatech-best-stock-ytd-nordic-biotech-healthcare-week-44\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Sector cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/sector-cases\/"},{"@type":"ListItem","position":4,"name":"Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44)"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39544"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=39544"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39544\/revisions"}],"predecessor-version":[{"id":39546,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/39544\/revisions\/39546"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/39226"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=39544"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=39544"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=39544"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}